Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 3.8% – Time to Sell?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) were down 3.8% on Monday . The stock traded as low as $20.55 and last traded at $20.52. Approximately 29,466 shares traded hands during trading, a decline of 87% from the average daily volume of 226,296 shares. The stock had previously closed at $21.33.

Analysts Set New Price Targets

Several research analysts recently commented on DNTH shares. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Guggenheim restated a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating on the stock. Wedbush reiterated an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Price Performance

The stock has a market cap of $613.84 million, a price-to-earnings ratio of -8.30 and a beta of 1.82. The business’s fifty day simple moving average is $22.34 and its 200 day simple moving average is $24.70.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DNTH. Quest Partners LLC lifted its stake in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after buying an additional 1,124 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after purchasing an additional 97,362 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Dianthus Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after purchasing an additional 7,854 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Dianthus Therapeutics during the third quarter valued at about $821,000. Finally, Braidwell LP raised its stake in shares of Dianthus Therapeutics by 34.6% during the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after purchasing an additional 126,836 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.